Skip to content

Exercise Hemodynamics in Patients With Pulmonary Fibrosis

Hemodynamic Study of the Pulmonary Circulation in Exercise in Patients With Pulmonary Fibrosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03706820
Enrollment
40
Registered
2018-10-16
Start date
2018-05-07
Completion date
2020-12-15
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise Pulmonary Hypertension

Brief summary

The study evaluates the rest and exercise hemodynamics of patients presenting either idiopathic fibrotic pulmonary disease or pulmonary fibrosis secondary to connective tissue disease.

Detailed description

Patients with fibrotic pulmonary disease of the above origin will undergo detailed assessment of functional status with the following examinations: pulmonary function tests, echocardiogram, 6 minute exercise test, cardiopulmonary exercise test (in the absence of contra-indications) and finally right heart catheterization. Hemodynamic assessment will take place at rest and at exercise following the exercise protocol that was recommended by Herve et al (ERJ 2015) using a cycle ergometer at bedside. The purposes of the study are: 1. to evaluate the response of the hemodynamic parameters at exercise compared to the resting parameters in this patient group. 2. to discriminate between precapillary from postcapillary etiology of pulmonary hypertension. 3. to correlate non-invasive parameters of functional limitation with invasive hemodynamic parameters. 4. to assess the prognostic role of exercise induced pulmonary hypertension in the specific patient group.

Interventions

None listed

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. diagnosis of pulmonary fibrosis secondary to connective tissue disease, according to the American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) revised classification criteria , or diagnosis of idiopathic fibrotic diffuse pulmonary disease according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines 2. Forced vital capacity (FVC) ≥ 40 %

Exclusion criteria

1. Presence of contra-indications to exercise tests, such as acute myocardial infarction, unstable angina, uncontrollable arrythmia or skeletal disease that limits the ability to exercise. 2. History of pulmonary embolism during the year before enrollment 3. Presence of severe valvular disease. 4. Current treatment with vasoactive drugs of the pulmonary circulation 5. Pulmonary wedge pressure (PAWP) at rest \> 15 mmHg

Design outcomes

Primary

MeasureTime frameDescription
Change in total pulmonary resistance (TPR) from rest to exercise2nd minute,4th minute, 6th minute, 8th minuteThe patient undergoes right heart catheterization and all hemodynamic variables are measured at rest and at exercise. TPR is derived by the following equation : mean pulmonary artery pressure/ cardiac output (mPAP/CO). TPR is measured at rest and at exercise following a specific protocol. The measurements are made at rest, then at the sequential exercise steps of increasing work resistance.

Countries

Greece

Contacts

Primary ContactEvangelia S Panagiotidou, MD
evangeliapanagiotidou@gmail.com+306949139509
Backup ContactGeorgia G Pitsiou, MD, PhD
gpitsiou@yahoo.gr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026